Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision

Published:December 27, 2019DOI:


      Brigham and Women's Hospital stage T2a squamous cell carcinomas, demonstrating a single high-risk feature, have a low risk of metastasis and death but an increased risk of local recurrence. Little evidence exists for the best treatment modality and associated outcomes in T2a squamous cell carcinoma.


      We aimed to compare outcomes for T2a squamous cell carcinoma treated by Mohs micrographic surgery compared with wide local excision with permanent sections.


      Retrospective review of an institutional review board–approved single-institution registry of T2a squamous cell carcinoma.


      Three hundred sixty-six primary T2a tumors were identified, including 240 squamous cell carcinomas (65.6%) treated with Mohs micrographic surgery and 126 (34.4%) treated with wide local excision. A total of 32.5% of patients were immunosuppressed and mean oncologic follow-up was 2.8 years. Local recurrence was significantly more likely after wide local excision (4.0%) than after Mohs micrographic surgery (1.2%) (P = .03). Multiple logistic regression demonstrated immunocompromised state (odds ratio [OR] 5.1; 95% confidence interval [CI] 1.1-23.3; P = .03) and wide local excision (OR 4.8; 95% CI 1.1-21.6; P = .04) associated with local recurrence; and wide local excision (OR 7.8; 95% CI 2.4-25.4; P < .001), high-risk head and neck location (OR 8.3; 95% CI 1.8-38.7; P = .004), and poor histologic differentiation (OR 4.7; 95% CI 1.4-15.4; P = .03) associated with poor outcomes (overall recurrence or disease-specific death).


      Mohs micrographic surgery provides improved outcomes in Brigham and Women's Hospital T2a squamous cell carcinoma.

      Key words

      Abbreviations used:

      CI (confidence interval), OR (odds ratio)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gonzalez J.L.
        • Reddy N.D.
        • Cunningham K.
        • Silverman R.
        • Madan E.
        • Nguyen B.M.
        Multiple cutaneous squamous cell carcinoma in immunosuppressed vs immunocompetent patients.
        JAMA Dermatol. 2019; 155: 625-627
        • Lanz J.
        • Bouwes Bavinck J.N.
        • Westhuis M.
        • et al.
        Aggressive squamous cell carcinoma in organ transplant recipients.
        JAMA Dermatol. 2019; 155: 66-71
        • Marrazzo G.
        • Zitelli J.A.
        • Brodland D.
        Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone.
        J Am Acad Dermatol. 2019; 80: 633-638
        • Karia P.S.
        • Jambusaria-Pahlajani A.
        • Harrington D.P.
        • Murphy G.F.
        • Qureshi A.A.
        • Schmults C.D.
        Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma.
        J Clin Oncol. 2014; 32: 327-334
        • Ruiz E.S.
        • Karia P.S.
        • Besaw R.
        • Schmults C.D.
        Performance of the American Joint Committee on Cancer staging manual, 8th edition vs the Brigham and Women's Hospital tumor classification system for cutaneous squamous cell carcinoma.
        JAMA Dermatol. 2019; 155: 819-825
        • Jambusaria-Pahlajani A.
        • Kanetsky P.A.
        • Karia P.S.
        • et al.
        Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.
        JAMA Dermatol. 2013; 149: 402-410
        • Ad Hoc Task Force
        • Connolly S.M.
        • Baker D.R.
        • et al.
        AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.
        J Am Acad Dermatol. 2012; 67: 531-550
        • Leitenberger J.J.
        • Rogers H.
        • Chapman J.C.
        • et al.
        Defining recurrence of nonmelanoma skin cancer after Mohs micrographic surgery: report of the American College of Mohs Surgery Registry and Outcomes Committee.
        J Am Acad Dermatol. 2016; 75: 1022-1031
        • Harris P.A.
        • Taylor R.
        • Thielke R.
        • Payne J.
        • Gonzalez N.
        • Conde J.G.
        Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inform. 2009; 42: 377-381
        • Harris P.A.
        • Taylor R.
        • Minor B.L.
        • et al.
        The REDCap Consortium: building an international community of software platform partners.
        J Biomed Inform. 2019; 95: 103208
        • Pugliano-Mauro M.
        • Goldman G.
        Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma.
        Dermatol Surg. 2010; 36: 1544-1553
        • Rowe D.E.
        • Carroll R.J.
        • Day Jr., C.L.
        Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection.
        J Am Acad Dermatol. 1992; 26: 976-990
        • Leibovitch I.
        • Huilgol S.C.
        • Selva D.
        • Hill D.
        • Richards S.
        • Paver R.
        Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years.
        J Am Acad Dermatol. 2005; 53: 253-260
        • Jambusaria-Pahlajani A.
        • Miller C.J.
        • Quon H.
        • Smith N.
        • Klein R.Q.
        • Schmults C.D.
        Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes.
        Dermatol Surg. 2009; 35: 574-585
        • Winkelhorst J.T.
        • Brokelman W.J.
        • Tiggeler R.G.
        • Wobbes T.
        Incidence and clinical course of de-novo malignancies in renal allograft recipients.
        Eur J Surg Oncol. 2001; 27: 409-413
        • Martinez J.C.
        • Otley C.C.
        • Stasko T.
        • et al.
        Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study.
        Arch Dermatol. 2003; 139: 301-306
        • Manyam B.V.
        • Garsa A.A.
        • Chin R.I.
        • et al.
        A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
        Cancer. 2017; 123: 2054-2060
        • Sun L.
        • Chin R.I.
        • Gastman B.
        • et al.
        Association of disease recurrence with survival outcomes in patients with cutaneous squamous cell carcinoma of the head and neck treated with multimodality therapy.
        JAMA Dermatol. 2019; 155: 442-447
        • Johnson T.M.
        • Rowe D.E.
        • Nelson B.R.
        • Swanson N.A.
        Squamous cell carcinoma of the skin (excluding lip and oral mucosa).
        J Am Acad Dermatol. 1992; 26: 467-484
        • Dzubow L.M.
        • Rigel D.S.
        • Robins P.
        Risk factors for local recurrence of primary cutaneous squamous cell carcinomas. Treatment by microscopically controlled excision.
        Arch Dermatol. 1982; 118: 900-902
        • National Comprehensive Cancer Network
        NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines, squamous cell skin cancer, version 1.2020.
        (Accessed June 15, 2019)
        • Brodland D.G.
        • Zitelli J.A.
        Surgical margins for excision of primary cutaneous squamous cell carcinoma.
        J Am Acad Dermatol. 1992; 27: 241-248